Protalix BioTherapeutics (PLX) Asset Utilization Ratio (2011 - 2026)
Protalix BioTherapeutics' quarterly Asset Utilization Ratio came in at 0.83 in Q1 2026, up 1.94% year-on-year from 0.81 in Q1 2025, and up 29.08% quarter-over-quarter from 0.64 in Q4 2025.
Protalix BioTherapeutics has reported Asset Utilization Ratio for 15 years, with the latest figure at 0.83 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 1.94% year-over-year to 0.83; the trailing twelve-month figure through Mar 2026 stood at 0.83 (up 1.94% YoY), and the FY2025 full-year result was 0.68, changed 0.1% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.83, up from 0.64 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.87 in Q2 2023, with the low at 0.42 in Q2 2024.
- Average Asset Utilization Ratio over 5 years is 0.73, with a median of 0.76 recorded in 2023.
- Year-over-year, Asset Utilization Ratio slumped 51.8% in 2024 and soared 93.76% in 2025.
- Tracing PLX's Asset Utilization Ratio over 5 years: stood at 0.85 in 2022, then retreated by 10.08% to 0.76 in 2023, then climbed by 3.9% to 0.79 in 2024, then declined by 19.01% to 0.64 in 2025, then advanced by 29.08% to 0.83 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.83 (Q1 2026), 0.64 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 0.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.83 |
| Dec 31, 2025 | 0.64 |
| Sep 30, 2025 | 0.77 |
| Jun 30, 2025 | 0.81 |
| Mar 31, 2025 | 0.81 |
| Dec 31, 2024 | 0.79 |
| Sep 30, 2024 | 0.60 |
| Jun 30, 2024 | 0.42 |
| Mar 31, 2024 | 0.68 |
| Dec 31, 2023 | 0.76 |
| Sep 30, 2023 | 0.72 |
| Jun 30, 2023 | 0.87 |
| Mar 31, 2023 | 0.67 |
| Dec 31, 2022 | 0.85 |
| Sep 30, 2022 | 0.81 |
| Jun 30, 2022 | 0.70 |
| Mar 31, 2022 | 0.61 |
| Dec 31, 2021 | 0.49 |
| Sep 30, 2021 | 0.51 |
| Jun 30, 2021 | 0.46 |
| Mar 31, 2021 | 0.62 |
| Dec 31, 2020 | 0.90 |
| Sep 30, 2020 | 0.80 |
| Jun 30, 2020 | 0.79 |
| Mar 31, 2020 | 0.97 |
| Dec 31, 2019 | 1.03 |
| Sep 30, 2019 | 0.71 |
| Jun 30, 2019 | 0.43 |
| Mar 31, 2019 | 0.24 |
| Dec 31, 2018 | 0.14 |
| Sep 30, 2018 | 0.15 |
| Jun 30, 2018 | 0.27 |
| Mar 31, 2018 | 0.30 |
| Dec 31, 2017 | 0.26 |
| Sep 30, 2017 | 0.29 |
| Jun 30, 2017 | 0.23 |
| Mar 31, 2017 | 0.13 |
| Dec 31, 2016 | 0.12 |
| Sep 30, 2016 | 0.10 |
| Jun 30, 2016 | 0.05 |
| Mar 31, 2016 | 0.04 |
| Mar 31, 2014 | 0.03 |
| Sep 30, 2013 | 0.10 |
| Jun 30, 2013 | 0.16 |
| Mar 31, 2013 | 0.47 |
| Dec 31, 2012 | 0.45 |
| Sep 30, 2012 | 0.45 |
| Jun 30, 2012 | 0.44 |
| Mar 31, 2012 | 0.14 |
| Dec 31, 2011 | 0.15 |
| Sep 30, 2011 | 0.11 |